Home LiteratureArticle Details
PMID: 11461089 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Vascular endothelial growth factor (VEGF) upregulates BCL-2 and inhibits apoptosis in human and murine mammary adenocarcinoma cells.

British journal of cancer ·Vol. 85 ·No. 2 ·2001-07-20 ·Pages 273-8

Pidgeon GP, Barr MP, Harmey JH, Foley DA, Bouchier-Hayes DJ

Abstract

Tumour progression is regulated by the balance of proliferation and apoptosis in the tumour cell population. To date, the role of vascular endothelial growth factor (VEGF) in tumour growth has been attributed to the induction of angiogenesis. VEGF has been shown to be a survival factor for endothelial cells, preventing apoptosis by inducing Bcl-2 expression. In both murine (4T1) and human (MDA-MB-231) metastatic mammary carcinoma cell lines, we found that VEGF upregulated Bcl-2 expression and anti-VEGF antibodies reduced Bcl-2 expression. These alterations in Bcl-2 expression were reflected by the levels of tumour cell apoptosis. VEGF resulted in reduced tumour cell apoptosis, whereas its inhibition with anti-VEGF neutralizing antibodies induced apoptosis directly in tumour cells. Therefore, in addition to its role in angiogenesis and vessel permeability, VEGF acts as a survival factor for tumour cells, inducing Bcl-2 expression and inhibiting tumour cell apoptosis.

MeSH Terms
Adenocarcinoma/pathology Animals Apoptosis/physiology Breast Neoplasms/pathology Endothelial Growth Factors/physiology Humans In Situ Nick-End Labeling Lymphokines/physiology Mammary Neoplasms, Experimental/pathology Mice Proto-Oncogene Proteins c-bcl-2/immunology,metabolism Tumor Cells, Cultured Up-Regulation/immunology,physiology Vascular Endothelial Growth Factor A Vascular Endothelial Growth Factors
Chemicals
Endothelial Growth Factors Lymphokines Proto-Oncogene Proteins c-bcl-2 Vascular Endothelial Growth Factor A Vascular Endothelial Growth Factors
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Pidgeon G P
Department of Surgery, Royal College of Surgeons in Ireland, Beaumont Hospital, Beaumont, Dublin 9, Ireland.
Barr M P
Harmey J H
Foley D A
Bouchier-Hayes D J
References (20)
20 references, click to expand
  1. Overexpression of Bcl-x(L) promotes chemotherapy resistance of mammary tumors in a syngeneic mouse model.
    Am J Pathol. 1999 Dec;155(6):1861-7 PMID: 10595916
  2. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation.
    Cancer Res. 1999 Jul 15;59(14):3374-8 PMID: 10416597
  3. Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: In vivo expression and antitumor activity.
    Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2573-8 PMID: 10688880
  4. Prognostic significance of apoptosis regulators in breast cancer.
    Endocr Relat Cancer. 1999 Mar;6(1):29-40 PMID: 10732784
  5. Tumor dormancy in vivo by prevention of neovascularization.
    J Exp Med. 1972 Aug 1;136(2):261-76 PMID: 5043412
  6. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid.
    Science. 1983 Feb 25;219(4587):983-5 PMID: 6823562
  7. Sustained-release endotoxin. A model for inducing corneal neovascularization.
    Invest Ophthalmol Vis Sci. 1991 Oct;32(11):2906-11 PMID: 1917394
  8. Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues.
    J Clin Invest. 1992 Jan;89(1):244-53 PMID: 1729274
  9. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death.
    Cell. 1993 Aug 27;74(4):609-19 PMID: 8358790
  10. Endotoxin is angiogenic.
    Int J Exp Pathol. 1994 Jun;75(3):191-6 PMID: 7522030
  11. Apoptosis in the pathogenesis and treatment of disease.
    Science. 1995 Mar 10;267(5203):1456-62 PMID: 7878464
  12. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression.
    Nat Med. 1995 Feb;1(2):149-53 PMID: 7585012
  13. A model of angiogenesis in the mouse cornea.
    Invest Ophthalmol Vis Sci. 1996 Jul;37(8):1625-32 PMID: 8675406
  14. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis.
    Cell. 1996 Aug 9;86(3):353-64 PMID: 8756718
  15. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor.
    Cell. 1998 Mar 20;92(6):735-45 PMID: 9529250
  16. Homologous up-regulation of KDR/Flk-1 receptor expression by vascular endothelial growth factor in vitro.
    J Biol Chem. 1998 Nov 6;273(45):29979-85 PMID: 9792718
  17. Vascular endothelial growth factor inhibits apoptotic death in hematopoietic cells after exposure to chemotherapeutic drugs by inducing MCL1 acting as an antiapoptotic factor.
    Cancer Res. 1998 Dec 1;58(23):5565-9 PMID: 9850095
  18. Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression.
    Am J Pathol. 1999 Feb;154(2):375-84 PMID: 10027396
  19. Lipopolysaccharide enhances the production of vascular endothelial growth factor by human pulp cells in culture.
    Infect Immun. 1999 Apr;67(4):1633-9 PMID: 10084996
  20. The role of endotoxin/lipopolysaccharide in surgically induced tumour growth in a murine model of metastatic disease.
    Br J Cancer. 1999 Dec;81(8):1311-7 PMID: 10604727
Article Info
Journal
British journal of cancer
Abbr.
Br J Cancer
ISSN
0007-0920
Published
2001-07-20
Pages
273-8
Language
English
Region
England
NLM ID
0370635
PMCID
PMC2364032
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com